FIELD: medicine.
SUBSTANCE: invention refers to a method for treating diabetic macular edema. Method comprises injecting a biodegradable implant into a vitreous body having readings thereon at a frequency from once every six months to once every nine months for at least three years, wherein the biodegradable implant comprises a continuous double-extruded rod containing dexamethasone homogeneously dispersed in the biodegradable polymer matrix; wherein the biodegradable polymer matrix consists of a mixture of poly (D,L-lactide-co-glycolide) (PLGA), having hydrophilic end groups, and poly (D,L-lactide-co-glycolide) (PLGA), having hydrophobic end groups.
EFFECT: method is therapeutically effective for treating diabetic macular edema and leads to the improvement of human visual acuity by 15 or more letters for at least three years.
7 cl, 7 dwg, 1 ex, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
EYE IMPLANTAT PREPARED BY DOUBLE EXTRUSION METHOD | 2005 |
|
RU2389479C2 |
INTRAOCULAR DRUG DELIVERY SYSTEMS | 2007 |
|
RU2440102C2 |
METHOD OF TREATING ATROPHIC AGE-RELATED MACULAR DEGENERATION | 2009 |
|
RU2521338C9 |
METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION | 2009 |
|
RU2668371C2 |
INTRAOCULAR SYSTEMS OF SUSTAINED-RELEASE DRUG DELIVERY AND METHOD OF TREATING OPHTHALMIC DISEASES | 2010 |
|
RU2532333C2 |
METHOD OF TREATING ELEVATED INTRAOCULAR PRESSURE USING INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEM | 2014 |
|
RU2664686C2 |
IMPLANT FOR PROLONGED DRUG DELIVERY | 2014 |
|
RU2641021C2 |
BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR LONG-TERM RELEASE OF PROTEIN | 2013 |
|
RU2676102C2 |
METHOD FOR PREDICTING DIABETIC MACULAR EDEMA AFTER INTRAVITREAL ADMINISTRATION OF A DEXAMETHASONE IMPLANT | 2022 |
|
RU2778970C1 |
INTRACHAMBER IMPLANTS WITH PROLONGED RELEASE OF THERAPEUTIC AGENT | 2011 |
|
RU2565445C2 |
Authors
Dates
2019-06-06—Published
2014-11-14—Filed